ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Verzenio — Outside U.S. revenue by Year
Verzenio — Outside U.S. revenue ($M) ($M)
Eli Lilly Verzenio — Outside U.S. revenue: $2,259M in FY2025, up 19.8% from a year earlier. That is the highest of the 9 years on record here.
Latest, FY2025
2,259
Period ended Dec 31, 2025
Change on a year earlier
+19.8%
1,886 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Verzenio — Outside U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,259 | +19.8% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 1,886 | +39.3% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 1,354 | +63.1% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 830 | +61.2% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 515 | +74.9% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 294 | +135.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 125 | +1,792.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 6.60 | – | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2020-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Verzenio — Outside U.S. revenue ($M), annual FY2017–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-verzenio-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.